About Us

At NoRD Bio, we harness the transformative potential of disease monitoring to redefine cancer care for patients and clinicians.

Our Mission

  • Enhancing Access: Developing innovative, cost-effective tools to make MRD testing widely available.
  • Simplifying Usability: Creating intuitive technologies with rapid turnaround times and actionable results for clinicians and patients.
  • Driving Better Outcomes: Enabling earlier relapse detection, personalized treatments, and improved survival rates through precise and reliable MRD monitoring.
We believe MRD monitoring has the power to change lives, offering hope and clarity in the complex fight against cancer. Together, we are unlocking the potential of MRD to benefit every patient, everywhere.

Leadership

Ignaty Leshchiner, PhD
Associate Professor in Computational Biomedicine at the Boston University School of Medicine. Ignaty is a leading academic in the field of cancer computational biology. Focused on applying new genomic technologies, computational analysis and AI methods unravelling biology behind tumor development, treatment evasion, and progression to metastasis.
Dimitri Livitz, PhD
As Head of Data Science and Genomics, Dimitri applies statistical and AI models to real-world cancer data to advance cancer therapies. Previously at the Broad Institute of Harvard and MIT, he studied cancer heterogeneity and treatment resistance, co-authoring high-profile publications in Nature, Nature Medicine, and Cell. He holds a PhD from Columbia University for his research in Bayesian experimental design, which has laid the foundation for his current work.
Paul Trukhanov
Experienced startup entrepreneur with expertise in biotechnology, healthcare, data-intensive software engineering, which resulted in two successful startup exits. Paul have previously build web-scale software systems and now Paul leads data analysis software development teams as a Software Architect in Machine Learning at Dana Farber Cancer Institute.
Elizaveta Leshchiner, PhD
Dr. Liza Leshchiner is focused on experimental and computational biology of cancer. She has strong expertise in technology and high-throughput assay development, including genomic and screening assays. She earned her Ph.D. from Harvard University and is leading a team of scientists at the Broad Institute of Harvard and MIT.
Andrew Jacobs, JD
As CEO Andy has a 40-year record of successfully starting, managing and growing multitude of small and medium sized companies, several of which were subsequently sold to public companies. He has served as CEO and a Board Member for companies in the area of computational services and data management for cancer patients, as well as in other fields, and has been heavily involved in several non-profit enterprises, including a foundation providing patient access to experimental cancer vaccines under FDA regulations.

Senior Advisors

Ida Pavlichenko, PhD
Ida is a serial entrepreneur, innovator, and R&D leader with experience across startups, academia, and government. Previously, she co-founded and led a medtech company pioneering biomaterials for medical implants. Recognized with awards like MIT TR Innovators Under 35 and MassNextGen, her focus is on translating advanced science into practical medical solutions that enhance patient care.
Roger Jacobs, MBA
Roger is an executive with over 40 years of management and business development experience. For the past 20 years he has been on the Board and/or acted in a CEO/CFO/COO capacity in a number of companies in SaaS, bioinformatics and biological services. In his spare time Roger enjoys renovating an historic mansion on Chautauqua Lake, NY

Partnering with us

We also specialize in Next-Generation Sequencing (NGS) assays for cancer research. Our precision-driven approach delivers groundbreaking insights into tumor biology, therapeutic efficacy, and patient outcomes, enabling our clients to make impactful advancements in cancer care. We partner with cancer therapeutics developers across the United States, collaborating with organizations ranging from innovative biotech startups to established pharmaceutical companies.

What sets us apart?

  • Unmatched Expertise: Our team brings years of experience and deep insight, customized to meet the unique challenges of our clients.
  • Innovative Approaches: With diverse backgrounds and cutting-edge methodologies, we develop creative, state-of-the-art solutions that drive progress.
  • Client-Centric Support: We are committed to equipping our clients with the tools, technologies, and expertise they need to excel in their research and development goals.